Pro-Dex Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Pro-Dex wird ein Gewinn- und Umsatzwachstum von 92.2% bzw. 2.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 86.7% pro Jahr wachsen soll.

Wichtige Informationen

92.2%

Wachstumsrate der Gewinne

86.7%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	2.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	10 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Investors Can Find Comfort In Pro-Dex's (NASDAQ:PDEX) Earnings Quality

Feb 16

Here's Why Pro-Dex (NASDAQ:PDEX) Can Manage Its Debt Responsibly

Feb 14

Pro-Dex, Inc.'s (NASDAQ:PDEX) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jan 24

Is Weakness In Pro-Dex, Inc. (NASDAQ:PDEX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 15

The Pro-Dex (NASDAQ:PDEX) Share Price Is Up 732% And Shareholders Are Delighted

Feb 26

Independent Director William Farrell Just Sold A Bunch Of Shares In Pro-Dex, Inc. (NASDAQ:PDEX)

Feb 13

We Like These Underlying Trends At Pro-Dex (NASDAQ:PDEX)

Feb 08

Pro-Dex EPS misses by $0.27, misses on revenue

Feb 04

Is Pro-Dex (NASDAQ:PDEX) A Risky Investment?

Jan 25

What Is The Ownership Structure Like For Pro-Dex, Inc. (NASDAQ:PDEX)?

Jan 11

How Much Are Pro-Dex, Inc. (NASDAQ:PDEX) Insiders Taking Off The Table?

Dec 28

With EPS Growth And More, Pro-Dex (NASDAQ:PDEX) Is Interesting

Dec 14

What Is Pro-Dex, Inc.'s (NASDAQ:PDEX) Share Price Doing?

Nov 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:PDEX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2025	51	5	N/A	6	1
6/30/2024	49	2	N/A	16	1
3/31/2024	49	2	5	6	N/A
12/31/2023	48	3	3	4	N/A
9/30/2023	47	5	2	3	N/A
6/30/2023	46	7	4	5	N/A
3/31/2023	48	8	-2	0	N/A
12/31/2022	44	7	-4	-3	N/A
9/30/2022	43	5	-2	-1	N/A
6/30/2022	42	5	-3	-1	N/A
3/31/2022	39	3	3	5	N/A
12/31/2021	41	5	-2	1	N/A
9/30/2021	39	6	-8	2	N/A
6/30/2021	38	6	-10	-2	N/A
3/31/2021	40	8	-8	0	N/A
12/31/2020	36	7	-4	3	N/A
9/30/2020	36	6	3	3	N/A
6/30/2020	35	6	4	5	N/A
3/31/2020	31	4	2	3	N/A
12/31/2019	29	4	3	4	N/A
9/30/2019	27	4	3	4	N/A
6/30/2019	27	4	2	3	N/A
3/31/2019	26	3	3	4	N/A
12/31/2018	25	3	3	3	N/A
9/30/2018	24	2	1	3	N/A
6/30/2018	22	2	2	3	N/A
3/31/2018	22	2	2	3	N/A
12/31/2017	23	2	N/A	4	N/A
9/30/2017	22	5	N/A	4	N/A
6/30/2017	22	5	N/A	3	N/A
3/31/2017	21	4	N/A	3	N/A
12/31/2016	20	4	N/A	2	N/A
9/30/2016	20	2	N/A	1	N/A
6/30/2016	19	1	N/A	0	N/A
3/31/2016	18	1	N/A	-1	N/A
12/31/2015	17	0	N/A	-1	N/A
9/30/2015	15	0	N/A	-2	N/A
6/30/2015	13	0	N/A	-1	N/A
3/31/2015	13	0	N/A	0	N/A
12/31/2014	11	-1	N/A	1	N/A
9/30/2014	11	-1	N/A	1	N/A
6/30/2014	11	-1	N/A	0	N/A
3/31/2014	10	-1	N/A	0	N/A
12/31/2013	11	-2	N/A	-1	N/A
9/30/2013	11	-2	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PDEXDas prognostizierte Gewinnwachstum (92.2% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: PDEXDie Erträge des Unternehmens (92.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: PDEXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: PDEXDie Einnahmen des Unternehmens (2.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: PDEXDie Einnahmen des Unternehmens (2.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PDEX in 3 Jahren voraussichtlich hoch sein wird

Pro-Dex Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 32%

Price target increased by 7.7% to US$28.00

Consensus EPS estimates fall by 15%, revenue upgraded

Price target decreased by 16% to US$26.00

Consensus EPS estimates fall by 27%

Price target decreased to US$30.00

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Consensus EPS estimates fall by 32%

Investors Can Find Comfort In Pro-Dex's (NASDAQ:PDEX) Earnings Quality

Here's Why Pro-Dex (NASDAQ:PDEX) Can Manage Its Debt Responsibly

New minor risk - Earnings quality

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Pro-Dex, Inc.'s (NASDAQ:PDEX) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Investor sentiment improves as stock rises 16%

Price target increased by 7.7% to US$28.00

Pro-Dex, Inc., Annual General Meeting, Dec 14, 2023

Pro-Dex, Inc. announced delayed annual 10-K filing

Investor sentiment improves as stock rises 17%

Pro-Dex (NASDAQ:PDEX) Has A Pretty Healthy Balance Sheet

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 15%, revenue upgraded

Price target decreased by 16% to US$26.00

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pro-Dex, Inc. Announces Board Elections

Insufficient new directors

First quarter 2023 earnings released: EPS: US$0.30 (vs US$0.29 in 1Q 2022)

Insufficient new directors

Pro-Dex (NASDAQ:PDEX) Could Be Struggling To Allocate Capital

Pro-Dex, Inc., Annual General Meeting, Nov 17, 2022

Pro-Dex: Growth Trends In Earnings, Return On Investment Contracting

Investor sentiment deteriorated over the past week

When Should You Buy Pro-Dex, Inc. (NASDAQ:PDEX)?

Full year 2022 earnings released: EPS: US$1.06 (vs US$1.17 in FY 2021)

Pro-Dex GAAP EPS of $0.38, revenue of $12.61M

Now 21% undervalued

Consensus EPS estimates fall by 27%

Price target decreased to US$30.00

Independent Director recently bought US$58k worth of stock

Is Now The Time To Look At Buying Pro-Dex, Inc. (NASDAQ:PDEX)?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is Pro-Dex (NASDAQ:PDEX) Using Too Much Debt?

Investor sentiment improved over the past week

Pro-Dex (NASDAQ:PDEX) Is Doing The Right Things To Multiply Its Share Price

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Investor sentiment deteriorated over the past week

Is Pro-Dex, Inc. (NASDAQ:PDEX) Potentially Undervalued?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Price target decreased to US$34.00

We Think Pro-Dex (NASDAQ:PDEX) Is Taking Some Risk With Its Debt

First quarter 2022 earnings released: EPS US$0.29 (vs US$0.33 in 1Q 2021)

Independent Director recently bought US$85k worth of stock

Investor sentiment deteriorated over the past week

Is It Too Late To Consider Buying Pro-Dex, Inc. (NASDAQ:PDEX)?

Full year 2021 earnings released: EPS US$1.17 (vs US$1.56 in FY 2020)

Investor sentiment deteriorated over the past week

A History Of Strong Growth Rates: Pro-Dex On Sale

The Return Trends At Pro-Dex (NASDAQ:PDEX) Look Promising

Price target increased to US$41.00

Consensus EPS estimates increase to US$1.20

Third quarter 2021 earnings released: EPS US$0.52 (vs US$0.31 in 3Q 2020)

What Is Pro-Dex, Inc.'s (NASDAQ:PDEX) Share Price Doing?

Investor sentiment improved over the past week

Is Weakness In Pro-Dex, Inc. (NASDAQ:PDEX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Investor sentiment deteriorated over the past week

The Pro-Dex (NASDAQ:PDEX) Share Price Is Up 732% And Shareholders Are Delighted

New 90-day low: US$24.95

Independent Director William Farrell Just Sold A Bunch Of Shares In Pro-Dex, Inc. (NASDAQ:PDEX)

Independent Director recently sold US$66k worth of stock

Investor sentiment deteriorated over the past week

We Like These Underlying Trends At Pro-Dex (NASDAQ:PDEX)

Second quarter 2021 earnings released: EPS US$0.087 (vs US$0.32 in 2Q 2020)

New 90-day low: US$26.71